2. Academic Validation
  3. Superiority of the Triple-Acting 5-HT6R/5-HT3R Antagonist and MAO-B Reversible Inhibitor PZ-1922 over 5-HT6R Antagonist Intepirdine in Alleviation of Cognitive Deficits in Rats

Superiority of the Triple-Acting 5-HT6R/5-HT3R Antagonist and MAO-B Reversible Inhibitor PZ-1922 over 5-HT6R Antagonist Intepirdine in Alleviation of Cognitive Deficits in Rats

  • J Med Chem. 2023 Oct 5. doi: 10.1021/acs.jmedchem.3c01482.
Katarzyna Grychowska 1,  Uriel López-Sánchez 2,  Mathieu Vitalis 3,  Geoffrey Canet 4,  Grzegorz Satała 5,  Agnieszka Olejarz-Maciej 1,  Joanna Gołębiowska 5,  Rafał Kurczab 5,  Wojciech Pietruś 5,  Monika Kubacka 1,  Christophe Moreau 2,  Maria Walczak 1,  Klaudia Blicharz-Futera 1,  Ophélie Bento 6 7,  Xavier Bantreil 6,  Gilles Subra 6,  Andrzej J Bojarski 5,  Frédéric Lamaty 6,  Carine Becamel 7,  Charleine Zussy 3,  Séverine Chaumont-Dubel 7,  Piotr Popik 5,  Hugues Nury 2,  Philippe Marin 7,  Laurent Givalois 3 4 8,  Paweł Zajdel 1
Affiliations

Affiliations

  • 1 Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Str., 30-688 Kraków, Poland.
  • 2 Univ. Grenoble Alpes, CNRS, CEA, IBS, F-38000 Grenoble, France.
  • 3 Molecular Mechanisms in Neurodegenerative Dementia (MMDN) Laboratory, University of Montpellier, EPHE-PSL, INSERM U1198, 34-095 Montpellier, France.
  • 4 Faculty of Medicine, Laval University, CR-CHUQ, G1 V 4G2 Québec City (QC), Canada.
  • 5 Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Str., 31-324 Kraków, Poland.
  • 6 IBMM, Université de Montpellier, CNRS, ENSCM, 34-293 Montpellier, France.
  • 7 Institut de Génomique Fonctionnelle, Université de Montpellier, CNRS, INSERM, 34-094 Montpellier, France.
  • 8 CNRS, 75-016 Paris, France.
PMID: 37797083 DOI: 10.1021/acs.jmedchem.3c01482
Abstract

The multifactorial origin and neurochemistry of Alzheimer's disease (AD) call for the development of multitarget treatment strategies. We report a first-in-class triple acting compound that targets serotonin type 6 and 3 receptors (5-HT-Rs) and Monoamine Oxidase type B (MAO-B) as an approach for treating AD. The key structural features required for MAO-B inhibition and 5-HT6R antagonism and interaction with 5-HT3R were determined using molecular dynamic simulations and cryo-electron microscopy, respectively. Bioavailable PZ-1922 reversed scopolamine-induced cognitive deficits in the novel object recognition test. Furthermore, it displayed superior pro-cognitive properties compared to intepirdine (a 5-HT6R antagonist) in the AD model, which involved intracerebroventricular injection of an oligomeric solution of Amyloid-β peptide (oAβ) in the T-maze test in rats. PZ-1922, but not intepirdine, restored levels of biomarkers characteristic of the debilitating effects of oAβ. These data support the potential of a multitarget approach involving the joint modulation of 5-HT6R/5-HT3R/MAO-B in AD.

Figures
Products